Streetbeat News

PRFX

PainReform Ltd.

https://www.painreform.com

Industry

Drug Manufacturers - Specialty & Generic

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Open

2.81

Mkt cap

1.8M

Volume

175K

High

3.27

P/E Ratio

-0.02

52-wk high

20.16

Low

2.81

Div yield

N/A

52-wk low

0.43

PainReform Ltd. announced initial topline data from its Phase 3 clinical trial for PRF-110, a post-surgical pain management drug. The data was received from Lotus Clinical Research.

Portfolio Pulse from

November 20, 2024 | 1:45 pm

PainReform Ltd. has received a notice from Nasdaq indicating it no longer meets the minimum stockholders' equity requirement for continued listing. The company must address this to maintain its Nasdaq listing.

Portfolio Pulse from

November 07, 2024 | 10:15 pm

Maxim Group has downgraded PainReform (NASDAQ:PRFX) from a Buy to a Hold rating, as per analyst Naz Rahman.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 1:33 pm

U.S. stocks edged higher with the Dow, NASDAQ, and S&P 500 showing slight gains. The Chicago Fed National Activity Index improved significantly in August. Kaival Brands, Nuvve Holding, and Treasure Global saw substantial stock price increases, while Elevai Labs, Jin Medical, and PainReform experienced declines.

Portfolio Pulse from Avi Kapoor

September 23, 2024 | 1:42 pm

Granite Point Mortgage Trust shares rose in pre-market trading after announcing dividends for common and preferred stocks. Several other stocks, including Nukkleus Inc. and Wheeler Real Estate Investment Trust, also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

September 23, 2024 | 9:46 am

PainReform shares are declining following the announcement of findings related to the compatibility of sutures in human clinical trials of their product PRF-110.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 4:26 pm

PainReform has announced findings from human clinical trials indicating that their product, PRF-110, is compatible with sutures. This development could enhance the product's marketability and adoption in medical procedures.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 12:33 pm

PainReform Ltd. (NASDAQ:PRFX) shares fell 32.1% after announcing a warrant exercise, reducing the exercise price from $4.80 to $1.60 per share, raising $1.58 million. The funds are for general corporate purposes, indicating potential liquidity needs. The company faces uncertainty amid clinical trials.

Portfolio Pulse from Vaishali Prayag

September 10, 2024 | 4:42 pm

PainReform shares are experiencing a decline following the company's decision to exercise warrants, resulting in $1.58 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 2:50 pm

PainReform has exercised warrants, resulting in gross proceeds of $1.58 million. This financial move could impact the company's liquidity and future operations.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 1:51 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.